These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 3301301)

  • 1. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
    Monk JP; Todd PA
    Drugs; 1987 Jun; 33(6):539-76. PubMed ID: 3301301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
    Balfour JA; McTavish D; Heel RC
    Drugs; 1990 Aug; 40(2):260-90. PubMed ID: 2226216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.
    Hoffman A; Lomnicky Y; Luria MH; Gilhar D; Friedman M
    Pharm Res; 1999 Jul; 16(7):1093-7. PubMed ID: 10450936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
    Heller F; Harvengt C
    Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of lipid-lowering drugs.
    Illingworth DR
    Drugs; 1988; 36 Suppl 3():63-71. PubMed ID: 3076124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of uremic hypertriglyceridaemia with bezafibrate.
    Norbeck HE; Anderson P
    Atherosclerosis; 1982 Aug; 44(2):125-36. PubMed ID: 7138614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of bezafibrate and probucol in hyperlipidaemia.
    Páez Moreno JP; González G
    Curr Med Res Opin; 1989; 11(8):523-32. PubMed ID: 2680288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
    Williams AJ; Baker F; Walls J
    Br J Clin Pharmacol; 1984 Sep; 18(3):361-7. PubMed ID: 6386024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats.
    Williams AJ; Baker FE; Walls J
    J Pharm Pharmacol; 1985 Oct; 37(10):741-3. PubMed ID: 2867148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.
    Raedsch R; Plachky J; Wolf N; Simonis G
    Eur J Drug Metab Pharmacokinet; 1995; 20(2):113-8. PubMed ID: 8582435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate.
    Oster P; Lang PD; Vollmar J; Schlierf G
    Res Exp Med (Berl); 1986; 186(6):435-41. PubMed ID: 3823619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F; Mannucci L; Mussoni L; Gianfranceschi G; Maderna P; Werba P; Franceschini G; Sirtori CR; Tremoli E
    Eur J Clin Pharmacol; 1992; 43(3):219-23. PubMed ID: 1425883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia.
    Wanner C; Wieland H; Schollmeyer P; Hörl WH
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S85-9. PubMed ID: 2044651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia.
    Eriksson M; Angelin B
    Eur J Clin Invest; 1987 Oct; 17(5):396-401. PubMed ID: 3121342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
    Rovellini A; Sommariva D; Branchi A; Maraffi F; Montalto C; Gandini R; Fasoli A
    Pharmacol Res; 1992 Apr; 25(3):237-45. PubMed ID: 1518767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.